Geron (GERN)

• Market cap: $809M
• 1 day: 2.42%
• 5 days: -3.79%
• 1 month: -27.01%
• 3 months: -56.06%
• 6 months: -68.72%
• Year to date: -64.72%
• 1 year: -65.49%
• 5 years: 5.83%
• 10 years: -68.01%
• Sector: Healthcare
• Industry: Biotechnology

About: Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Employees: 229

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

153% more call options, than puts

Call options by funds: $8.03M | Put options by funds: $3.18M

106% more first-time investments, than exits

New positions opened: 66 | Existing positions closed: 32

39% more repeat investments, than reductions

Existing positions increased: 89 | Existing positions reduced: 64

20% more funds holding in top 10

Funds holding in top 10: 5 [Q3] → 6 (+1) [Q4]

11% more funds holding

Funds holding: 255 [Q3] → 283 (+28) [Q4]

3.44% less ownership

Funds ownership: 84.38% [Q3] → 80.94% (-3.44%) [Q4]

25% less capital invested

Capital invested by funds: $2.31B [Q3] → $1.73B (-$577M) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3.50 176% upside
• Avg. target: $4.10 223% upside
• High target: $5 294% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Needham Gil Blum 12% 1-year accuracy 19 / 157 met price target	294% upside $5	Buy Reiterated	12 Mar 2025
Scotiabank Greg Harrison 24% 1-year accuracy 10 / 41 met price target	215% upside $4	Sector Outperform Maintained	27 Feb 2025
Stifel Stephen Willey 25% 1-year accuracy 5 / 20 met price target	215% upside $4	Buy Maintained	27 Feb 2025
Barclays Peter Lawson 5% 1-year accuracy 1 / 21 met price target	215% upside $4	Overweight Maintained	27 Feb 2025
B. Riley Securities Kalpit Patel 9% 1-year accuracy 1 / 11 met price target	176% upside $3.50	Buy Maintained	18 Feb 2025